Share This Page

 
Now on Twitter!

Follow us: ChinaBio

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
Free White Paper

>> Download now...

D-Pharm Outlicenses Stroke Drug to Wanbang Biopharma

publication date: Nov 9, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

D-Pharm Ltd. of Israel has outlicensed the China rights to its treatment for ischemic stroke to Wanbang Biopharmaceuticals Ltd. The drug, DP-b99, is currently in a Phase III multi-national clinical trial. D-Pharm and Wanbang will co-develop DP-b99 in China, with Wanbang underwriting the cost for the first 450 China patients in a Phase III trial. D-Pharm will be responsible for any additional patients. More details...

Stock Symbol: (TASE: DPRM)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2012
May 23-24, 2012
Suzhou, China

>>More events...
Partner Events

China Healthcare Investment Conference 2012
March 13-15, 2012
Shanghai, China


Shanghai CEO Conference
March 28-29, 2012
Shanghai, China

>>More details...
Other Events

China Pharmaceutical R&D Summit
April 23-26, 2012
Shanghai, China


Biosimilars Asia 2012
April 23-26, 2012
Shanghai, China


Vaccines China 2012
April 23-26, 2012
Shanghai, China

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners